VX 150

Drug Profile

VX 150

Alternative Names: VX-150

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Analgesics; Small molecules
  • Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 26 Jan 2017 Vertex Pharmaceuticals plans a phase II proof-of-concept trial for neuropathic pain and acute pain
  • 01 Sep 2016 Vertex Pharmaceuticals completes a phase II trial in Pain (in patients with knee osteoarthritis) (In adults, In the elderly) in USA (NCT02660424)
  • 26 Jan 2016 Efficacy and safety data from a phase II trial in pain (in patients with knee osteoarthritis) released by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top